639858-63-2

Basic information

• Product Name: Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI)
• Synonyms: Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI)
• CAS NO: 639858-63-2
• Molecular Formula: C₁₀H₉BrFNO
• Molecular Weight: 258.0869632
• Product Categories: AMIDE
• Mol File: 639858-63-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI)(639858-63-2)
• EPA Substance Registry System: Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI)(639858-63-2)

Safety Data

• Hazardous Substances Data: 639858-63-2(Hazardous Substances Data)

Usage

General Description

Benzamide, 3-bromo-N-cyclopropyl-4-fluoro- (9CI) is a chemical compound with the molecular formula C10H8BrFN2O. It is an organic compound that contains benzene, bromine, fluorine, nitrogen, and oxygen atoms. This chemical is classified as a benzamide, and it also contains a cyclopropyl group. It is used in various research and laboratory applications, and its precise uses and properties may vary depending on the specific context and application.

Upstream product

• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 765-30-0 Cyclopropylamine 

Downstream Products

• 639858-65-4 N-cyclopropyl-4-fluoro-3-(4-oxobutyl)benzamide 
• 639858-64-3 N-cyclopropyl-3-(4,4-diethoxybutyl)-4-fluorobenzamide 

Relevant articles and documents

2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein α, β, R2, R3, R4, R5, R8, R9, X1, X6, and X7 are defined in the specification. The compounds of formula 1 are receptor-interacting protein kinase 2 (RIPK2) inhibitors for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 107 to 208; examples 1 to 109; table 1). An exemplary compound is e.g. N-cyclopropyl-2-fluoro-5-(l-(2-fluoroethyl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-oxo-2,3-dihydro-lH-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide (example 1).

Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2- ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2

Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibi